Study investigating metabolomics (analysis of molecules produced from cell activity) as a new measurement method for liver enzyme functio

Not Applicable

• Conditions: Impact of CYP2C9 genotype and CYP2C9 inhibiting drugs in healthy volunteers; Not Applicable

• Registration Number: ISRCTN88417663
• Lead Sponsor: niversity of Dundee

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-05-21
• Last Update Posted: 6 February 2023
• Study Completion: 2023-03-01

Recruitment & Eligibility

• Status: Stopped
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

1. Aged 18 - 60 years
2. Caucasian (to limit genetic variation as much as possible)
3. Not known to have diabetes
4. No daily treatment with antidiabetic medication, statins, amitriptyline or other drugs that inhibit or require CYP2C9 or CYP3A4 metabolism
5. No cognitive impairment or visual impairment
6. Known CYP2C9 genotype – either normal (wild type”) or two reduced function alleles

Exclusion Criteria

1. Heterozygous CYP2C9 genotype i.e. only one reduced function allele
2. Use of any antifungal drug within the last month
3. Recent involvement (<30 days) in a clinical trial
4. Pregnancy or planning to conceive
5. Inability/unwillingness to comply with the protocol
6. Anaemia

Study & Design

• Study Type: Interventional
• Study Design: Not specified